share_log

Cytek Biosciences Analyst Ratings

Cytek Biosciencesのアナリスト評価

Benzinga ·  2023/11/09 09:01
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/09/2023 40% Morgan Stanley $8 → $7 Maintains Equal-Weight
10/24/2023 60% Morgan Stanley $13 → $8 Maintains Equal-Weight
10/16/2023 100% Piper Sandler $15 → $10 Maintains Overweight
07/19/2023 Raymond James Initiates Coverage On → Market Perform
05/11/2023 160% Morgan Stanley $14 → $13 Maintains Equal-Weight
05/10/2023 140% Goldman Sachs $14 → $12 Maintains Buy
03/07/2023 200% Piper Sandler $18 → $15 Maintains Overweight
03/02/2023 180% Morgan Stanley $15 → $14 Maintains Equal-Weight
03/02/2023 180% Goldman Sachs $16 → $14 Maintains Buy
08/18/2022 220% Piper Sandler $12 → $16 Maintains Overweight
08/12/2022 200% Morgan Stanley $11 → $15 Maintains Equal-Weight
08/11/2022 240% Goldman Sachs $15 → $17 Maintains Buy
07/14/2022 200% Goldman Sachs $12 → $15 Maintains Buy
05/16/2022 140% Piper Sandler $17 → $12 Maintains Overweight
05/13/2022 120% Morgan Stanley $18 → $11 Maintains Equal-Weight
05/12/2022 140% Goldman Sachs $14 → $12 Maintains Buy
04/13/2022 180% Goldman Sachs $28 → $14 Maintains Buy
02/15/2022 260% Morgan Stanley $27 → $18 Maintains Equal-Weight
08/17/2021 Cowen & Co. Initiates Coverage On → Outperform
08/17/2021 420% Morgan Stanley → $26 Initiates Coverage On → Equal-Weight
08/17/2021 460% Goldman Sachs → $28 Initiates Coverage On → Buy
08/17/2021 460% Piper Sandler → $28 Initiates Coverage On → Overweight

What is the target price for Cytek Biosciences (CTKB)?

The latest price target for Cytek Biosciences (NASDAQ: CTKB) was reported by Morgan Stanley on November 9, 2023. The analyst firm set a price target for $7.00 expecting CTKB to rise to within 12 months (a possible 40.00% upside). 9 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Cytek Biosciences (CTKB)?

The latest analyst rating for Cytek Biosciences (NASDAQ: CTKB) was provided by Morgan Stanley, and Cytek Biosciences maintained their equal-weight rating.

When is the next analyst rating going to be posted or updated for Cytek Biosciences (CTKB)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytek Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytek Biosciences was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.

Is the Analyst Rating Cytek Biosciences (CTKB) correct?

While ratings are subjective and will change, the latest Cytek Biosciences (CTKB) rating was a maintained with a price target of $8.00 to $7.00. The current price Cytek Biosciences (CTKB) is trading at is $5.00, which is out of the analyst's predicted range.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする